CNBC January 9, 2026
Key Points
– Abivax stock rallied in 2025, far outpacing peers, as the French biotech surprised investors with a stellar data readout in July for its lead asset – an ulcerative colitis medicine.
– Now, analysts say the French biotech could be bought by a larger peer for as much $23 billion.
– “Abivax ticks all the boxes for a strategic acquisition,” Stifel analyst Damien Choplain told CNBC.
Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion.
Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing...
Today's Sponsors
Today's Sponsor